Posted by Defense World Staff on Feb 26th, 2026
Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans during its fourth-quarter and full-year...
More of this article »